In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli

J. H. Jorgensen, S. A. Crawford, G. A. Alexander

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The in vitro activities of two new beta-lactam antibiotics, moxalactam disodium (LY 127935) and cefotaxime (HR-756), were compared with cefoxitin, cefamandole, cefuroxime, cephalothin, and, in some instances, carbenicillin, gentamicin, and amikacin against aerobic gram-negative bacilli. Test isolates included normally cephalosporin-resistant members of the Enterobacteriaceae and Pseudomonas spp. and a variety of nonfermentative or oxidase-positive bacteria. Both moxalactam and cefotaxime demonstrated impressive in vitro activities, against both groups of microorganisms. The two new drugs were clearly more active than any of the other beta-lactam antibiotics against species of Escherichia, Citrobacter, Enterobacter, Klebsiella, Proteus, Providencia, Pseudomonas, and Serratia. An additive or synergistic effect could also be demonstrated with the majority of Pseudomonas and Serratia isolates when either moxalactam or cefotaxime was combined with amikacin.

Original languageEnglish (US)
Pages (from-to)937-942
Number of pages6
JournalAntimicrobial agents and chemotherapy
Issue number6
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli'. Together they form a unique fingerprint.

Cite this